BIOMAT Database Logo BIOMAT Database Logo

Hormonal regulation of serum lipoprotein(a) levels. Contrasting effects of growth hormone and insulin-like growth factor-I. 1995

H Olivecrona, and A G Johansson, and E Lindh, and S Ljunghall, and L Berglund, and B Angelin
Department of Surgery, Karolinska Institute, Huddinge University Hospital, Sweden.

In response to treatment with growth hormone, serum levels of lipoprotein(a) increase, while those of LDL cholesterol decrease. To establish if increased levels of insulin-like growth factor-I may be of importance for these changes, we analyzed serum lipoprotein concentrations in 11 male patients with idiopathic osteoporosis who were treated with growth hormone (2 IU.m-2.d-1) or insulin-like growth factor-I (80 micrograms.kg-1.d-1) in a randomized, double-blind, cross-over study. LDL cholesterol was reduced by 0.7 mmol/L (P < .01) during growth hormone treatment but was not affected when the same patients received insulin-like growth factor-I. In contrast, mean lipoprotein(a) levels increased from 519 to 571 mg/L (P < .03) in response to growth hormone but were reduced from 538 to 478 mg/L (P < .04) during treatment with insulin-like growth factor-I. These results indicate that growth hormone exerts its effects on lipoprotein metabolism independent of insulin-like growth factor-I. Furthermore, the results suggest that treatment with insulin-like growth factor-I may reduce lipoprotein(a) levels.

UI MeSH Term Description Entries
D007334 Insulin-Like Growth Factor I A well-characterized basic peptide believed to be secreted by the liver and to circulate in the blood. It has growth-regulating, insulin-like, and mitogenic activities. This growth factor has a major, but not absolute, dependence on GROWTH HORMONE. It is believed to be mainly active in adults in contrast to INSULIN-LIKE GROWTH FACTOR II, which is a major fetal growth factor. IGF-I,Somatomedin C,IGF-1,IGF-I-SmC,Insulin Like Growth Factor I,Insulin-Like Somatomedin Peptide I,Insulin Like Somatomedin Peptide I
D008076 Cholesterol, HDL Cholesterol which is contained in or bound to high-density lipoproteins (HDL), including CHOLESTEROL ESTERS and free cholesterol. High Density Lipoprotein Cholesterol,Cholesterol, HDL2,Cholesterol, HDL3,HDL Cholesterol,HDL(2) Cholesterol,HDL(3) Cholesterol,HDL2 Cholesterol,HDL3 Cholesterol,alpha-Lipoprotein Cholesterol,Cholesterol, alpha-Lipoprotein,alpha Lipoprotein Cholesterol
D008078 Cholesterol, LDL Cholesterol which is contained in or bound to low density lipoproteins (LDL), including CHOLESTEROL ESTERS and free cholesterol. LDL Cholesterol,Cholesteryl Linoleate, LDL,LDL Cholesteryl Linoleate,Low Density Lipoprotein Cholesterol,beta-Lipoprotein Cholesterol,Cholesterol, beta-Lipoprotein,beta Lipoprotein Cholesterol
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010024 Osteoporosis Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis. Age-Related Osteoporosis,Bone Loss, Age-Related,Osteoporosis, Age-Related,Osteoporosis, Post-Traumatic,Osteoporosis, Senile,Senile Osteoporosis,Osteoporosis, Involutional,Age Related Osteoporosis,Age-Related Bone Loss,Age-Related Bone Losses,Age-Related Osteoporoses,Bone Loss, Age Related,Bone Losses, Age-Related,Osteoporoses,Osteoporoses, Age-Related,Osteoporoses, Senile,Osteoporosis, Age Related,Osteoporosis, Post Traumatic,Post-Traumatic Osteoporoses,Post-Traumatic Osteoporosis,Senile Osteoporoses
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013006 Growth Hormone A polypeptide that is secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Growth hormone, also known as somatotropin, stimulates mitosis, cell differentiation and cell growth. Species-specific growth hormones have been synthesized. Growth Hormone, Recombinant,Pituitary Growth Hormone,Recombinant Growth Hormone,Somatotropin,Somatotropin, Recombinant,Growth Hormone, Pituitary,Growth Hormones Pituitary, Recombinant,Pituitary Growth Hormones, Recombinant,Recombinant Growth Hormones,Recombinant Pituitary Growth Hormones,Recombinant Somatotropins,Somatotropins, Recombinant,Growth Hormones, Recombinant,Recombinant Somatotropin

Related Publications

H Olivecrona, and A G Johansson, and E Lindh, and S Ljunghall, and L Berglund, and B Angelin
Effects of short-term treatment with insulin-like growth factor-I and growth hormone on serum lipoprotein (a) in growth hormone-deficient adults.
February 1998, European journal of endocrinology,
H Olivecrona, and A G Johansson, and E Lindh, and S Ljunghall, and L Berglund, and B Angelin
Growth hormone increases and insulin-like growth factor-I decreases circulating lipoprotein(a)
April 1997, European journal of endocrinology,
H Olivecrona, and A G Johansson, and E Lindh, and S Ljunghall, and L Berglund, and B Angelin
Serum levels of growth hormone-binding protein and insulin-like growth factor-I during puberty.
August 1992, Clinical endocrinology,
H Olivecrona, and A G Johansson, and E Lindh, and S Ljunghall, and L Berglund, and B Angelin
Regulation of cartilage growth by growth hormone and insulin-like growth factor I.
July 1991, Pediatric nephrology (Berlin, Germany),
H Olivecrona, and A G Johansson, and E Lindh, and S Ljunghall, and L Berglund, and B Angelin
Fetal serum levels of insulin, growth hormone and insulin-like growth factor-I in concordant and discordant twin gestations.
August 2001, The Journal of maternal-fetal medicine,
H Olivecrona, and A G Johansson, and E Lindh, and S Ljunghall, and L Berglund, and B Angelin
Serum insulin-like growth factor I levels in growth hormone-deficient adults: influence of sex steroids.
January 2004, Hormone research,
H Olivecrona, and A G Johansson, and E Lindh, and S Ljunghall, and L Berglund, and B Angelin
Effects of cadmium and zinc on plasma levels of growth hormone, insulin-like growth factor I, and insulin-like growth factor-binding protein 3.
January 2005, Biological trace element research,
H Olivecrona, and A G Johansson, and E Lindh, and S Ljunghall, and L Berglund, and B Angelin
Measurement of salivary insulin-like growth factor-I in acromegaly: comparison with serum insulin-like growth factor-I and growth hormone concentrations.
September 1994, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies,
H Olivecrona, and A G Johansson, and E Lindh, and S Ljunghall, and L Berglund, and B Angelin
Regulation of insulin-like growth factor I gene expression by growth hormone.
December 1986, Proceedings of the National Academy of Sciences of the United States of America,
H Olivecrona, and A G Johansson, and E Lindh, and S Ljunghall, and L Berglund, and B Angelin
Hormonal regulation of insulin-like growth factor binding proteins and insulin-like growth factor I (IGF-I) secretion in porcine stromal-vascular cultures.
October 1996, Journal of animal science,
Copied contents to your clipboard!